Holen Sie sich die Stockscreener-App
568.26
0.71%
-4.06
Vorhandelsmarkt:
567.51
-0.75
-0.13%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$572.32
Offen:
$570
24-Stunden-Volumen:
2.94M
Relative Volume:
1.24
Marktkapitalisierung:
$211.18B
Einnahmen:
$45.20B
Nettoeinkommen (Verlust:
$6.87B
KGV:
31.24
EPS:
18.1888
Netto-Cashflow:
$6.75B
1W Leistung:
+6.72%
1M Leistung:
+15.45%
6M Leistung:
-9.22%
1J Leistung:
+19.63%
1-Tages-Spanne:
$555.91
$574.00
1-Wochen-Bereich:
$495.04
$587.49
52-Wochen-Spanne:
$435.27
$643.99
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Compare TMO vs DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | DZ Bank | Buy |
| 2025-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-12-01 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-09-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-19 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-07-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Thermo Fisher Scientific (NYSE:TMO) Faces A Margin Test - Kalkine Media
Thermo Fisher Scientific Q2 up 10% to USD 11.99 billion - Medical Buyer
Thermo Fisher stock trades steadily as diagnostics and biopharma demand support earnings trajectory - AD HOC NEWS
Thermo Fisher Scientific Inc. (TMO) Leads with RSI of 73 Amid Ea - GuruFocus
Thermo Fisher Scientific Inc. Revenue Breakdown – BX:TN8 - TradingView
Billionaire Investor Dumps Thermo Fisher, Cuts Danaher As He Pares Life Sciences Tools BetsDanaher (NY - Benzinga
Thermo Fisher Scientific Launches Thermo Scientific™ InstaFlux™ to Help Food Microbiology Labs Simplify Workflows in Pathogen and Environmental Testing - 01net
Thermo Fisher posts strong Q2 2026 with 10% rev... - Pluang
Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider - GlobeNewswire Inc.
Company News for July 24, 2026 - Yahoo Finance
Deutsche Bank Adjusts Thermo Fisher Scientific Price Target to $635 From $630, Maintains Buy Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Thermo Fisher Scientific to $660 From $615, Maintains Overweight Rating - marketscreener.com
Rothschild & Co Redburn Raises Price Target on Thermo Fisher Scientific to $625 From $610, Maintains Buy Rating - marketscreener.com
Thermo Fisher Raised Full-Year Guidance After a Standout Q2 Earnings Call - TIKR.com
RBC Raises Price Target on Thermo Fisher Scientific to $580 From $490, Keeps Sector Perform Rating - marketscreener.com
Barclays Adjusts Thermo Fisher Scientific Price Target to $650 From $625, Maintains Overweight Rating - marketscreener.com
Thermo Fisher raises 2026 outlook after 10% growth in Q2 - Yahoo Finance
Bernstein Adjusts PT on Thermo Fisher Scientific to $575 From $520, Maintains Market Perform Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Thermo Fisher Scientific to $650 From $570, Maintains Buy Rating - marketscreener.com
Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing Role - Yahoo Finance
Thermo Fisher stock holds steady ahead of earnings - Ad-hoc-news.de
THERMO FISHER SCIENTIFIC INC : LEERINK PARTNERS RAISES TARGET PRICE TO $620 FROM $600 - Bitget
Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades - Yahoo! Finance Canada
Thermo Fisher Scientific Q2 Earnings Call Highlights - Yahoo Finance
TMO Q2 FY2026 earnings call - finance.biggo.com
Is It Too Late to Buy Thermo Fisher Scientific Inc (TMO) After 8 - GuruFocus
THERMO FISHER SCIENTIFIC INC : EVERCORE ISI RAISES TARGET PRICE TO $615 FROM $570 - Bitget
Thermo Fisher Scientific Inc Stock 12‑Month Price Target Raised to $606.79, Implies 15% Upside - TradingView
Jefferies Adjusts Price Target on Thermo Fisher Scientific to $630 From $585, Maintains Buy Rating - Moomoo
Thermo Fisher Scientific Inc.'s stock price skyrockets to $572.32, marking an impressive 8.71% surge - Smartkarma
Thermo Fisher Stock Jumps on Second Quarter Results - WFMZ.com
Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlig - GuruFocus
Thermo Fisher Scientific Inc. stock rises Thursday, outperforms market - MarketWatch
Thermo Fisher Scientific (TMO) Reports Strong Q2 2026 Earnings a - GuruFocus
Thermo Fisher Scientific Inc Stock Price Live, Charts & News - The Economic Times
Thermo Fisher Points to Improving End-Market ActivityThermo Fisher Scientific (NYSE:TMO) - Benzinga
Leerink Partners Adjusts Price Target on Thermo Fisher to $620 From $600, Maintains Outperform Rating - marketscreener.com
Thermo Fisher TMO Stock Draws Bullish Calls Ahead Of Q2 - timothysykes.com
Thermo Fisher Scientific Reports Second Quarter 2026 Results - BioSpace
Thermo Fisher Scientific (NYSE:TMO) Gains Focus In A Selective Market - Kalkine Media
Why Is Thermo Fisher (TMO) Stock Rocketing Higher Today - Yahoo Finance
Thermo Fisher Q2 revenue rises 10% to $11.99 billion - grafa.com
Thermo Fisher Scientific Inc Stock (TMO) Moved Up by 9.89% on Jul 23: A Full Analysis - TradingKey
Thermo Fisher Stock Draws Bullish Targets Ahead Of Q2 - StocksToTrade
Thermo Fisher Scientific Inc (TMO) Stock Forecasts - Yahoo Finance
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $615 From $570 - marketscreener.com
Thermo Fisher Stock Climbs As Analysts Hike Targets Ahead Q2 - timothysykes.com
TMO Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-Market - The Globe and Mail
Thermo Fisher Rises as Instrument Demand Recovery Lifts Outlook - Bloomberg.com
Thermo Fisher (NYSE:TMO) shares gain as instrument margins exceed sales growth - TechStock²
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):